SCHEMBL1103439

SCHEMBL1103439

c1ccc(-c2c3ccccc3c(-c3ccc4c5cccc6cccc(c7cccc3c74)c65)c3cnc4ccccc4c23)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ GPR3 P46089 1/20 0.37
▸ ESR1 P03372 2/20 0.35
▸ ESR2 Q92731 2/20 0.35
▸ ALDH1A1 P00352 5/20 0.35
▸ HPGD P15428 3/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MET P08581 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103253 0.92 KDM4E (0.41) MAPTLMNASMN1; SMN2NPC1RECQL
SCHEMBL1103604 0.88 KDM4E (0.38) MAPTLMNASMN1; SMN2NPC1RECQL
SCHEMBL1103546 0.88 MET (0.39) MAPTLMNASMN1; SMN2NPC1RECQL
SCHEMBL1103461 0.88 ALDH1A1 (0.40) MAPTLMNASMN1; SMN2NPC1RECQL
SCHEMBL1103462 0.87 MAPT (0.42) MAPTLMNASMN1; SMN2NPC1RECQL
SCHEMBL1103379 0.87 MAPT (0.44) MAPTLMNASMN1; SMN2NPC1RECQL
SCHEMBL1103419 0.85 ALDH1A1 (0.36) MAPTLMNASMN1; SMN2NPC1RECQL
SCHEMBL1103394 0.85 ALDH1A1 (0.39) MAPTLMNASMN1; SMN2NPC1RECQL
SCHEMBL1103487 0.84 MAPT (0.42) MAPTLMNASMN1; SMN2NPC1RECQL
SCHEMBL1103459 0.82 ESR1 (0.41) MAPTLMNASMN1; SMN2NPC1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MAPT 3162/4885LMNA 2738/4885SMN1; SMN2 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback